Portugues Portugues

Abstract

Introduction: Febrile Neutropic (NF) is a typical and frequent cytotropic, and may be a symptom of oncohematology after a cycle of chemotherapy. Most infectious diseases cannot be determined, with the main symptom being of unknown origin. Empirical antifungal therapies are initiated in cases of NF due to severe infection. Objective: To describe the profile of patients diagnosed with NF, the most used antifungals including time of onset and duration, and the most prevalent fungi in the oncohematology unit of a tertiary hospital in the Federal District. Method: Retrospective, descriptive, observational and detailed methodological approach, developed in a tertiary hospital in the Federal District. Data for the year 2020 were collected from all patients who used antifungals in the oncohematology unit diagnosed with febrile neutropenia. Results: A total of 97 patients were obtained, 43 had a diagnosis of febrile neutropenia. Among the antifungals that stood out in empirical use were: fluconazole (83.7%), voriconazole (60.5%) and anidulafungin (34.9%). Among the previous bril patients with neutropenia, 95.34% underwent anticancer chemotherapy in the surgery at diagnosis. Conclusion: The profile of antifungal drugs is in accordance with the literature being the first line of treatment, however in our study the azole class was predominant. This study determines the predominant profile of patients who evolved with male NF, diagnosed with AML, previous treatment with chemotherapy and with comorbidities.